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α-Fetoprotein (AFP) messenger RNA (mRNA) in the peripheral blood of patients with
hepatocellular carcinoma (HCC) may indicate hematogenous spread of HCC.  This
study examined the presence of AFP mRNA in the blood of 148 patients, in terms of
clinical parameters, tumor metastasis and survival rate.  For the prospective study, 109
patients with HCC were followed in the period between March 1996 and March 1999.
AFP mRNA in the blood was examined by means of nested reverse transcription poly-
merase chain reaction.  AFP mRNA was detected in the blood in 23 (15.5%) of 148
patients with HCC.  AFP mRNA in the blood was significantly correlated with protein
induced by vitamin K absence or antagonist II level, higher AFP level (200 IU/mL or
more) and extrahepatic metastases, but not with tumor size, number of tumor nodules
or tumor-nodule-metastasis stage.  This prospective study confirmed that intra- and
extra-hepatic metastases developed more frequently in the 22 AFP mRNA-positive
patients than in the 87 AFP mRNA-negative patients (P < 0.01).  The cumulative survival
rate was significantly lower in the former than in the latter (P < 0.01).  In conclusion,
AFP mRNA in the blood is closely related to hematogenous spread and might be a good
predictor of metastasis and poorer survival rate in HCC patients.
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Abbreviations:  AFP, α-fetoprotein; bp, base pair; CT, computed tomography; HCC, hepatocellular carci-
noma; mRNA, messenger RNA; PCR, polymerase chain reaction; PIVKA-II, protein induced by vitamin K
absence or antagonist II; RT-PCR, reverse transcription-PCR; TNM, tumor-nodule-metastasis
Hepatocellular carcinoma (HCC) is a common
malignancy throughout the world, especially in
Asian countries.  Despite advances in diagnos-
tic tools and therapeutic options, intra- or extra-
hepatic tumor metastases are frequently found
after surgical and medical treatments such as
hepatic resection, transcatheter arterial emboli-
zation , percutaneous ethanol injection and liver
transplantation (Yokoyama et al., 1990; Behghiti
et al., 1991; Okuda, 1992; Nagasue et al., 1993;
Adachi et al., 1995; Zhou, et al, 1996).  HCC me-
tastases include intrahepatic metastases and/or
de novo tumors (Chen et al., 1989; Heu et al.,
1991; Sheu et al., 1993; Nakano et al., 1994;
Takenaka et al., 1994; Tarao et al., 1994;
Toyosaka et al., 1996; Kumada et al., 1997; Kubo
et al., 1998).   Therefore, it is important to detect
micrometastases in order to choose effective
therapeutic approaches.
α-Fetoprotein (AFP), a serum protein pro-
duced in large amounts during fetal life, rapidly
reduces from late fetal life and is essentially
scarce in normal adults.  The synthesis of AFP
is often associated with the development of
HCC and yolk sac tumors (Gitlin and Boesman,
1966; Adinolfi et al., 1975).  The detection of se-
rum AFP provides a useful marker for diagnosis
and prognosis of these tumors (Adinolfi et al.,
1975).  However, the serum AFP level does not
always correspond to the clinical stage of HCC
(Okuda et al., 1975; Nomura et al., 1989; Inoue
et al., 1994; Suehiro et al., 1994; Nakagawa et
al., 1999).  Recent molecular biological tech-
niques have provided a method for detecting
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malignant cells in the peripheral blood by
amplification of messenger RNA (mRNA) of
various genes specific to a particular cell type
from peripheral blood mononuclear cells
(Smith et al., 1991; Mattano et al., 1992;
Moreno et al., 1992; Tada et al., 1993; Brandt et
al., 1996; Krüger et al., 1996; Nomoto et al.,
1996; Ishikawa et al., 1998).  AFP mRNA has
been demonstrated to be one of the candidate
molecules for detecting HCC cells in the blood
(Matsumura et al., 1994, 1995, 1999;  Komeda et
al., 1995; Jiang et al., 1997; Lemoine et al., 1997;
Louha et al., 1997; Nambu et al., 1997; Omichi-
Funaki et al., 1997, 1998; Wong et al., 1997; ; Luo
et al., 1999; Okuda et al., 1999).  With this
background, this study examined AFP mRNA
in patients with HCC using nested reverse
transcription polymerase chain reaction (RT-
PCR), in terms of clinical parameters, tumor
metastasis and survival rate.
Subjects and Methods
Patients and cell line
All patients were admitted to Tottori University
Hospital between March 1996 and March 1999.
Samples were obtained from the 148 patients
with HCC.  Informed consent was obtained
from each patient or from family members if the
patient could not make a decision.  Table 1 sum-
marized the patients’ profiles.  In 116 of 148 pa-
tients, HCC was histologically classified ac-
cording to the General Rules for the Clinical and
Pathological Study of Primary Liver Cancer in
Japan (Liver Cancer Study Group of Japan, 1989)
by tumor biopsies under the guidance of ultra-
sonography.  The remaining patients were diag-
nosed by several imaging modalities such as
ultrasonography, computed tomography (CT),
magnetic resonance imaging or angiography.
On the basis of these findings, the tumors were
classified according to the tumor-nodule-
metastasis (TNM) classification of the General
Rules for the Clinical and Pathological Study of
Primary Liver Cancer in Japan (Liver Cancer
Study Group of Japan, 1989) when the sample
was obtained.  Extrahepatic metastases were
Table 1. Profiles of HCC patients
Number of patients 148
Age (year)   66 ± 9
Gender (male/female)   94/54
Etiology of liver disease
HBV-related   33
HCV-related   96
HBV- and HCV-related     4
Alcoholic     5
Cryptogenic   10
Underlying liver disease
Chronic hepatitis   19
Cirrhosis
Child-Pugh grade A   67
Child-Pugh grade B   36
Child-Pugh grade C   26
TNM stage*
I   10
II   30
III   27
IVA   54
IVB   27
Tumor differentiation†
Well   40 (34.5%)
Moderate   65 (56.0%)
Poor   11 (  9.5%)
Serum AFP (ng/mL)
Median 159
Range     1  –   332,500
Serum PIVKA-II (mAU/mL)‡
Median   80
Range     4 – 1,270,000
AFP, α-fetoprotein; HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; HCV, hepatitis C virus;
PIVKA-II, protein induced by vitamin K absence
or antagonist II; TNM, tumor-nodule-metastasis.
* Clinical staging of the tumor was assessed accord-
ing to the TNM system of the General Rules for
the Clinical and Pathological Study of Primary
Liver Cancer in Japan on the basis of imaging
studies.
† Tumor biopsies were performed in 116 lesions and
classified according to the General Rules for the
Clinical and Pathological Study of Primary Liver
Cancer in Japan.
‡ Serum PIVKA-II levels were measured in 126 pa-
tients.
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detected by means of interviews, physical ex-
aminations and imaging techniques such as
chest X-ray, scintigraphy or CT.  The mean dia-
meters of the main tumors were 1.7 ± 0.4 cm in
stage I, 2.5 ± 1.3 cm in stage II, 3.7 ± 1.6 cm in
stage III, 3.3 ± 1.8 cm in stage IVA and 4.6 ± 4.1
cm in stage IVB.  No HCC patients underwent
treatment in the 2 months before the blood
samples were obtained.
Samples were also obtained from healthy
volunteers, who agreed to donate blood.  A
human hepatic carcinoma cell line, HepG2 cells
known to produce AFP, was kindly supplied by
Prof. Kenzo Sato of the Dept. of Molecular Bio-
chemistry, School of Life Sciences, Faculty of
Medicine, Tottori University.  For the prospec-
tive study, 109 patients (72 males and 37 fe-
males) with a median age of 66 ± 9 years and a
range of 34–80 years were enrolled.  Four
(3.7%) of 109 patients underwent hepatic re-
section, 71 (65.1%) were treated medically by
transcatheter arterial embolization and/or
percutaneous ethanol injection and 33 (30.3%)
remained untreated because of advanced liver
dysfunction, advanced liver cancer or the deci-
sion of each patient.  These patients were exa-
mined every 1 or 2 months at our outpatient
clinic for the detection of metastasis by the
measurement of tumor markers, AFP and pro-
tein induced by vitamin K absence or antagonist
II (PIVKA-II), every 1 or 2 months, ultrasonog-
raphy every 3 months and CT every 6 months.
The patients who developed a diffuse, infiltra-
tive HCC were not treated.  The patients were
followed up for a mean period of 16.2 ± 11.2
months.
Extraction of RNA
Five milliliters of heparinized blood were col-
lected from each patient.  RNA was extracted
from blood nuclear cells and HepG2 cells.  Pe-
ripheral mononuclear cells that may have con-
tained tumor cells were separated by discontin-
uous gradient centrifugation using a Ficoll-
Paque (Amersham-Pharmacia-Biotech,
Buckinghamshire, United Kingdom).  Total
RNA from mononuclear cells was extracted
with an RN easy Mini Kit (QIAGEN, Hilden,
Germany), which was based on the acid-
guanidium phenol-chloroform method and stor-
ed at –80°C until use.
Synthesis of complementary DNA
(cDNA)
One microgram of RNA was heated at 65°C for
10 min and cooled rapidly on ice, diluted to 13-
mL buffer with 45-mmol/L Tris (pH 8.3), 68-
mmol/L KCl, 9-mmol/L MgCl2, 15-mmol/L 1,4-
dithiorethreitol, 0.2-mg random hexadeoxynu-
cleotides, RNA guard (porcine), 0.8-µg/mL
RNase/DNase-free bovine serum albumin, 1.8-
mmol/L each dNTP, and Moloney Murine Leu-
kemia Virus reverse transcriptase (First-Strand
cDNA synthesis kit, Amersham-Pharmacia-
Biotech).  cDNA was synthesized by means of
incubation at 37°C for 60 min.  It was then
heated at 94 °C for 5 min for inactivation of re-
verse transcriptase, cooled rapidly and stored at
–20°C until use for the 1st PCR.
Sequence of primers used in nested
PCR
The sequences of primers used in the experi-
ment were as follows.  The primers for the AFP
gene were i) 5'-ACA GCA GCC ACT TGT
TGC CAA-3' (nucleotides 1413 to 1433) and
ii) 5'-CTC TTC AGC AAA GCA GAC TTC-3'
(nucleotides 1809 to 1829) for the outer prim-
ers; and iii) 5'-GCT GAC ATT ATT ATC GGA
CAC-3' (nucleotides 1473 to 1493) and iv) 5'-
AGC CTC AAG TTG TTC CTC TGT-3' (nu-
cleotides 1734 to 1754) for the inner primers.
The PCR amplification of the β-globin gene
was done to confirm the successful extraction
of mRNA from blood nuclear cells and HepG2
cells.  The primer sequences for the β-globin
gene were v) 5'-TGG TCT CCT TAA ACC TGT
CTT G-3' and vi) 5'-ACA CAA CTG TGT TCA
CTA GC-3' for the outer primers; and vii) 5'-
GTC TCC TTA AAC CTG TCT TG-3' and viii)
5'- ACA ACT GTG TTC ACT AGC-3' for the
inner primers.  The sense and antisense primers
described above were selected from different
exons to distinguish amplification of RNA from
contamination of DNA (Saiki et al., 1988).
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Nested RT-PCR
One microliter of cDNA solution was mixed
with 9 µL of the PCR reaction mixture contain-
ing 20-mmol/L Tris-HCl (pH 8.0), 100-mmol/L
KCl, 0.1-mmol/L EDTA, 0.5% Tween 20, 1-
mmol/L 1,4-dithiothreitol, 50% glycerol, 15-
mmol/L Mg2+, 1 mmol of each primer (Nos. i, ii, v
and vi) and 0.25-unit Taq polymerase (Gene Taq;
Wako Pure Chemical Ind., Osaka, Japan).  The
reaction mixture was overlaid with mineral oil
(Perkin Elmer, Foster City, CA) and heated at
95°C for 5 min.  It was subjected to a total of 35
cycles of heat at 94°C for 30 s, 54°C for 30 s and
72°C for 1 min with a thermal cycler (Gene Amp
PCR System 9600-R, Perkin-Elmer).  The reac-
tion terminated by heating at 72°C for 7 min
and cooling at 4°C.  One microliter of the am-
plified product was then used in the 2nd PCR.
One microliter of the amplified sample was
mixed with the same buffer as in the 1st PCR
for the 2nd PCR, except that the primers were
inner primers (Nos. iii, iv, vii and viii).  The am-
plification program was also the same as for the
1st PCR.  Three microliters of the above sec-
ondary amplified products were electrophores-
ed on a 1.8% agarose gel containing ethidium
bromide and photographed on a UV transil-
luminator (ATTO densitograph, ATTO Corpo-
ration, Tokyo, Japan).  The amplified products
of AFP and β-globin were 240 and 167 base
pair (bp), respectively.
Assay for AFP and PIVKA-II
Serum AFP and PIVKA-II concentrations were
measured with a chemiluminescence assay
(Wako Pure Chemical) and an electrochemilu-
minescence assay (Eizai Pharmaceutical Co.,
Tokyo), respectively.
Statistics
Statistical analysis was performed with the
Mann-Whitney U test.  The χ2 test was used for
statistical analysis between group frequencies.
The cumulative overall and metastasis-free
survival rates were calculated by the Kaplan-
Meier method.  Survival curves were compared
with a generalized Wilcoxon test.  A P value
less than 0.05 was considered significant.
Results
A specific band for the amplified AFP gene
(240 bp) was noted in the samples obtained
from HepG2 cells and an HCC patient with
AFP mRNA, but not in the sample from a
healthy volunteer (Fig. 1).
AFP mRNA in the peripheral blood was
detected in 23 (15.5%) of 148 patients with
HCC.  The frequency of positive patients in
each TNM stage was as follows: 1 of 10 patients
(10.0%) in stage I, 4 of 30 patients (13.3%) in
stage II, 4 of 27 patients (14.8%) in stage III, 7
of 54 patients (13.0%) in stage IVA and 7 of 27
patients (25.9%) in stage IVB (Table 2).  Al-
though the frequency tended to be higher in
stage IVB, there was no statistical significance.
HCC patients with AFP mRNA in the
peripheral blood were analyzed in relation to tu-
mor size, number of tumor nodules, the pres-
ence of portal vein thrombosis, portocaval
shunt, intrahepatic metastasis, extrahepatic
Fig. 1.  Nested reverse transcription-polymerase
chain reaction of α-fetoprotein (AFP) messenger
RNA (mRNA).  bp, base pair; HCC, hepatocellular
carcinoma.
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metastasis and serum tumor markers (AFP and
PIVKA-II) (Tables 2 and 3).  The largest tumor
was described in cases with two or more tumors
in the liver.  Tumor diameter was not signifi-
cantly different between the HCC patients with
AFP mRNA in the blood and those without
AFP mRNA.  The incidence of AFP mRNA in
the blood was not correlated with tumor size.
The number of tumor nodules in the liver
was not significantly different between the
HCC patients with AFP mRNA in the blood and
those without AFP mRNA.  The incidence of
AFP mRNA in the blood was not correlated
with the number of tumor nodules (Table 2).
Serum AFP concentration was higher in the
HCC patients with AFP mRNA (median: 1209
ng/mL, range: 9–319,900 ng/mL) than in the
patients without AFP mRNA (median: 125 ng/
mL, range: 1–332,500 ng/mL), the value being
not statistically significant (Fig. 2, Table 3).
When the patients were divided into 2 groups
according to serum AFP concentration, the inci-
Table 2. AFP mRNA in the blood of 148 HCC patients
Number AFP mRNA in blood P value
of Positive Negative Positive rate
patients [23] [125]  (%)
Tumor diameter ≥ 5 cm 26 5 21 19.2 NS
< 5 cm 122 18 104 14.8
Number of tumors ≥ 3 90 17 73 18.9 NS
< 3 58 6 52 10.3
AFP ≥ 200 ng/mL 64 15 49 23.4 < 0.05
< 200 ng/mL 84 8 76 9.5
PIVKA-II* ≥ 40   mAU/mL 72 10 62 13.9 NS
< 40   mAU/mL 54 8 46 14.8
TNM stage† I 10 1 9 10.0
II 30 4 26 13.3 NS
III 27 4 23 14.8
IVA 54 7 47 13.0
IVB 27 7 20 25.9 NS
Portal thrombosis Present 27 7 20 25.9
Absent 121 16 105 13.2
Portocaval shunt Present 37 3 34 8.1 NS
Absent 111 20 91 18.0
Extrahepatic metastasis Present 27 8 19 29.6 < 0.05
Absent 121 15 106 12.4
[   ], number of patients.
AFP, α-fetoprotein; HCC, hepatocellular carcinoma; mRNA, messenger RNA; NS, not significant;
PIVKA-II, protein induced by vitamin K absence or antagonist II; TNM, tumor-nodule-metastasis.
* Serum PIVKA-II levels were measured in 126 patients.
† Clinical staging of the tumor was assessed according to TNM system of the General Rules for Clinical and
Pathological Study of Primary Liver Cancer in Japan on the basis of imaging studies.
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Fig. 2.  Serum α-fetoprotein (AFP) concentrations in 23
patients with AFP messenger RNA (mRNA) in the
blood (median: 1209 ng/mL, range; 9–319,900 ng/mL)
and 125 patients without AFP mRNA (median: 125 ng/
mL, range; 1–332,500 ng/mL).  [  ], number of patients.
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dence of AFP mRNA in the blood was signifi-
cantly higher in the patients with 200 ng/mL or
more (23.4%) than those with less than 200 ng/
mL (9.5%; P < 0.05; Table 2).  PIVKA-II concen-
tration in the serum was significantly higher in
HCC patients with AFP mRNA in the blood
(76,443 ± 298,178 mAU/mL) than in the patients
without AFP mRNA (12,209 ± 50,415 mAU/mL;
P < 0.05).  However, when the patients were di-
vided into 2 groups according to PIVKA-II con-
centration, the incidence of AFP mRNA was
not different between the patients with PIVKA-
II concentrations of 40 mAU/mL or more and
those with less than 40 mAU/mL (Table 2).
The presence of portal thrombosis was
found in 7 (30.4%) of the 23 patients with AFP
mRNA in the blood and in 20 (16.0%) of the
Table 3.  Profiles of 148 patients with or without AFP mRNA
    AFP mRNA in blood P value
Positive Negative
Number of patients     23 125
Age (year)     65.7 ± 8.8   66.1 ± 8.6 NS
Gender (male/female)     14/9   80/45 NS
Etiology of liver disease HBV-related       7   26
HCV-related    15   81
HBV- and HCV-related       0     4 NS
Alcoholic       0     5
Cryptogenic       1     9
Underlying liver disease Chronic hepatitis       4   15
Cirrhosis
Child-Pugh grade A       6   61 < 0.05
Child-Pugh grade B       4   32
Child-Pugh grade C       9   17
Tumor diameter (cm)       3.3 ± 2.9  3.3 ± 2.3 NS
Number of tumors       8.9 ± 8.4  7.2 ± 7.8 NS
TNM stage* I, II       5   35 NS
III , IV     18   90
Tumor differentiation† Well       8 (40.0%)   32 (33.3%) NS
Moderate or poor     12 (60.0%)   64 (66.7%)
Serum AFP (ng/mL) Median 1209 125 NS
Range       9  –   319,900     1 – 332,500
Serum PIVKA-II (mAU/mL)‡ Median   151   73.5 < 0.05
Range     10 – 1,270,000     4 – 409,000
AFP, α-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; mRNA, messenger RNA; NS, not signifi-
cant; PIVKA-II, protein induced by vitamin K absence or antagonist II; TNM, tumor-nodule-metastasis.
* Clinical staging of the tumor was assessed according to the TNM system of the General Rules for the
Clinical and Pathological Study of Primary Liver Cancer in Japan on the basis of imaging studies.
† Tumor biopsies were performed in 116 lesions (20 cases in the AFP mRNA-positive group and 96 cases in
the AFP mRNA-negative group) and classified according to the General Rules for the Clinical and
Pathological Study of Primary Liver Cancer in Japan.
‡ Serum PIVKA-II was measured in 126 patients (18 in the AFP mRNA-positive group and 108 in the AFP
mRNA-negative group).
125 patients without AFP mRNA (Table 2).
The presence of a portocaval shunt was found in
3 (13.0%) of the 23 patients with AFP mRNA in
the blood and in 34 (27.2%) of the 125 patients
without AFP mRNA (Table 2).  Thus, AFP
mRNA in the blood did not correlate with portal
thrombosis or a portocaval shunt.
Extrahepatic metastases were noted in 8
(34.8%) of the 23 patients with AFP mRNA in
the blood and 19 (15.2%) of the 125 patients
without AFP mRNA, the value being signifi-
cantly higher in the former than in the latter (P <
0.05; χ2 test).  When the patients were classified
according to the presence or absence of extra-
hepatic metastases, AFP mRNA in the blood
was detected in 8 (29.6%) of the 27 patients
with extrahepatic metastases and in 15 (12.4%)
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of the 121 patients without extrahepatic metas-
tases, the value being statistically significant (P
< 0.05; Table 2).
Aspartate aminotransferase and alanine
aminotransferase concentrations in the serum
were significantly higher in the 23 HCC patients
with AFP mRNA in the blood (aspartate amino-
transferase; 203 ± 297 IU/L, alanine amino-
transferase; 113 ± 134 IU/L) than in the 125 pa-
tients without AFP mRNA (104 ± 116, P <
0.01,72 ± 61 IU/L, P < 0.05).
Table 4 summarizes the profiles of 109 pa-
tients undergoing follow-up studies which
disclosed the cause of death in 51 patients
(46.8%); 35 died from HCC progression, 9
from hepatic failure, 3 from gastrointestinal
Table 4.  Profiles of the 109 HCC patients with or without AFP mRNA
AFP mRNA in blood P value
Positive Negative
Number of patients     22 87
Age (year)     65.4 ± 8.9 65.6 ± 8.9 NS
Gender (male/female)     13/9 59/28 NS
Etiology of liver disease HBV-related       7 18
HCV-related     14 54
HBV- and HCV-related       0   3 NS
Alcoholic       0   4
Cryptogenic       1   8
Underlying liver disease Chronic hepatitis       3 12
Cirrhosis
Child-Pugh grade A       6 48 < 0.05
Child-Pugh grade B       4 21
Child-Pugh grade C       9   6
Tumor diameter (cm)       3.3 ± 3.0   3.5 ± 2.5 NS
Number of tumors       9.0 ± 8.6   6.1 ± 7.3 NS
TNM stage* I, II       5 28 NS
III , IV     17 59
Tumor differentiation† Well       7 (36.8%) 23 (36.5%) NS
Moderate or poor     12 (63.2%) 40 (63.5%)
Serum AFP (ng/mL) Median 1951 63 NS
Range       9   –  319,900   1 – 332,500
Serum PIVKA-II  (mAU/mL)‡ Median   101 30 NS
Range     10 – 1,270,000   4 – 409,000
AFP, α-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; mRNA,
messenger RNA; NS, not significant; PIVKA-II, protein induced by vitamin K absence or antagonist II;
TNM, tumor-nodule-metastasis.
* Clinical staging of the tumor was assessed according to the TNM system of the General Rules for the
Clinical and Pathological Study of Primary Liver Cancer in Japan on the basis of imaging studies.
† Tumor biopsies were performed in 82 lesions (19 cases in the AFP mRNA-positive group and 63 cases in
the AFP mRNA-negative group) and classified according to the General Rules for the Clinical and
Pathological Study of Primary Liver Cancer in Japan.
‡ Serum PIVKA-II was measured in 94 patients (17 in the AFP mRNA-positive group and 77 in the AFP
mRNA-negative group).
bleeding and 4 from other diseases.  AFP mRNA
was noted in 8, 4, 0 and 0 patients, respectively.
Extrahepatic metastasis was observed in 13
(11.9 %) patients (7 in the AFP mRNA-positive
and 6 in the AFP mRNA-negative group).
Tumor metastases were found in the lung in 6
patients, the bone in 3, the adrenal glands in 4,
the spleen in 1 and the pharynx in 1.
Next, the following parameters were ana-
lyzed:  the cumulative rate of the extrahepatic
metastasis, the cumulative rate of intra- and
extra-hepatic metastases and the cumulative
survival rate for each AFP mRNA status.  The
cumulative rate of extrahepatic metastasis was
similar between the 2 groups (data not shown).
However, the cumulative rate of intra- and
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extra-hepatic metastases was significantly
higher in the 22 AFP mRNA-positive patients
than that in the 87 AFP mRNA-negative pa-
tients (P < 0.01; Fig. 3).  The cumulative surviv-
al rate was significantly lower in the 22 AFP
mRNA-positive group than in the 87 AFP
mRNA-negative group (P < 0.01; Fig. 4).
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Fig. 4.  Cumulative survival curve calculated by the
Kaplan-Meier method for 22 patients with positive
α-fetoprotein (AFP) messenger RNA (mRNA)  and
87 patients with negative AFP mRNA.  The
difference is statistically significant (P < 0.01).   [  ],
number of patients.
Fig. 3.  Rates of intra- and extra-hepatic metastases
calculated by the Kaplan-Meier method for 22 pa-
tients with positive α-fetoprotein (AFP) messenger
RNA (mRNA) and 87 patients with negative AFP
mRNA.  The difference is statistically significant (P
< 0.01).   [  ], number of patients.
Discussion
In this study, AFP mRNA in the blood was
detected in the 23 (15.5%) of the total 148 HCC
patients.  Previous studies showed the positive
rate of AFP mRNA in the peripheral blood to be
from 25 to 95% of HCC patients (Matsumura et
al., 1994, 1999; Komeda et al., 1995; Jiang et al.,
1997; Lemoine et al., 1997; Louha et al., 1997;
Nambu et al., 1997; Luo et al., 1999; Okuda et al.,
1999).  The lower frequency in the present study
might be partly due to the selection of patients,
in whom extrahepatic metastases were noted
only in 27 patients.  Furthermore, there were
more patients with AFP non-producing HCC in
the present study than in the previous reports
(Matsumura et al., 1994; Jiang et al., 1997).
The next possible reason is the difference in the
timing of the examination of blood samples.
Louha et al. (1997) reported that AFP mRNA
producing cells in the blood were detected after
locoregional therapy such as transcatheter
arterial embolization or percutaneous ethanol
injection.  Matsumura et al. (1994) and Okuda
et al. (1999) also showed that tumor cells do not
always circulate in the blood, but may appear
intermittently.  We analyzed the blood sample
before therapy or at least 2 months after ther-
apy.
Next, we investigated the relationship be-
tween AFP mRNA in the blood and the clinical
parameters of HCC.  The AFP mRNA in the
blood did not correlate with tumor size, number
of tumor nodules, presence of portal thrombosis
and portocaval shunt, or TNM stage.  Clinical
significance of AFP mRNA in the blood is con-
troversial even now (Matsumura et al., 1994,
1999; Komeda et al., 1995; Lemoine et al., 1997;
Louha et al., 1997; Nambu et al., 1997; Luo et al.,
1999).  What is interesting is that this study
confirmed a significant correlation between se-
rum aspartate aminotransferase or alanine ami-
notransferase concentration and AFP mRNA in
the blood.  The present study also demonstrated
that the HCC patients with high levels of serum
AFP showed higher detectable rates of AFP
mRNA in the blood than those with low levels
of serum AFP.  The frequency of AFP mRNA
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in the blood, however, was not so much higher
in the HCC patients with a high AFP level
(23.4%).  This result suggests that the serum
AFP level does not necessarily reflect the pres-
ence of circulating cells with AFP mRNA.  In
other words, the serum AFP level is not a useful
test to indicate the presence of circulating HCC
cells.  Nambu et al. (1997) and Luo et al. (1999)
showed that the PIVKA-II value may be a good
indicator of AFP mRNA in the blood.  The posi-
tive rate of AFP mRNA in the blood was not
different between PIVKA-II-positive patients
(40 mAU/mL and more) and -negative patients
(less than 40 mAU/mL) in this study, although
HCC patients with AFP mRNA-positive in the
blood had higher PIVKA-II values than those
with lower PIVKA-II.  It is conceivable that the
positivity of AFP mRNA did not correlate with
the serum PIVKA-II value, because PIVKA-II-
positive and AFP-negative HCCs are commonly
experienced and the nested RT-PCR in the pres-
ent study does not detect AFP non-producing
cells.
In agreement with some previous research
(Matsumura et al., 1994, 1999; Komeda et al.,
1995; Louha et al., 1997), we found that the
positivity of AFP mRNA in the blood was asso-
ciated with extrahepatic metastasis.  The detec-
tion of AFP mRNA was clearly more frequent
in the patients with extrahepatic metastasis than
those without.  This suggests that circulating
AFP producing cells might be responsible for
extrahepatic metastasis.
The present study compared the survival rate
and intra- and extra-hepatic metastases, in which
there were no differences in serum AFP levels,
PIVKA-II levels or TNM stages.  Matsumura et
al. (1999) reported that the incidence of extra-
hepatic metastasis was significantly higher in
the AFP mRNA-positive group than that in the
AFP mRNA-negative group.  However, the
extrahepatic metastasis was not significantly
different between the 2 groups in the present
study.  The cumulative rate of intra- and extra-
hepatic metastases was significantly higher in
the patients positive with AFP mRNA in the
blood than in the patients without.  This result
may indicate that tumor cells in the systemic
circulation are responsible not only for extra-
hepatic metastasis but also intrahepatic metas-
tasis, which have been considered to be caused
mainly by the spreading of cancer cells via the
portal vein (Toyosaka et al., 1996).  Funaki et
al. (1997) reported that cancer cells released
from the primary tumor to the systemic circula-
tion might participate in intrahepatic metas-
tasis.  Since the liver provides an essentially fa-
vorable environment for HCC cells, the inci-
dence of intrahepatic metastasis through the
systemic circulation might be more frequent
than previously considered.  Therefore, it is
reasonable to assume that HCC patients who
undergo liver transplantation do not always
have good prognoses and often experience me-
tastases in the transplanted livers (Zhou et al.,
1996).
In the present follow-up study, we found
that the cumulative survival rate was signifi-
cantly poorer in the AFP mRNA-positive group
than that in the AFP mRNA-negative group.
Matsumura et al. (1999) found that overall sur-
vival was similar between patients in AFP
mRNA-positive and -negative groups, but the
survival rates in continuous AFP mRNA-posi-
tive patients was poorer than that in continuous
AFP mRNA-negative patients.  This result
shows that the presence of AFP mRNA cells in
the blood might be a predictive factor in HCC
patients.  Since the present AFP mRNA-posi-
tive group had more severe underlying liver dis-
ease than the AFP mRNA-negative group, this
might affect the survival rate.  However, it is
indisputable that the high frequency of intra-
and extra-hepatic metastases in the AFP
mRNA-positive group was responsible for their
poor prognoses.
In conclusion, AFP mRNA in the blood of
HCC patients related to PIVKA-II levels and
was significantly detectable in patients with an
AFP level of 200 IU/mL or more, or with extra-
hepatic metastases.  Thus, the detection of AFP
mRNA in the blood might be a predictor for
tumor metastasis and survival of HCC patients.
M. Kawakami et al.
56
References
 1 Adachi E, Maeda T, Matsumata T, Shirabe K,
Kinukawa N, Sugimachi K, et al.  Risk factors for
intrahepatic recurrence in human small hepato-
cellular carcinoma.  Gastroenterology 1995;108:
768–775.
 2 Adinolfi A, Adinolfi M, Lessof MH.  Alpha-feto-
protein during development and in disease.  J
Med Genet 1975;12:135–151.
 3 Behghiti J, Panis Y, Farges O, Benhamou JP,
Fekete F.  Intrahepatic recurrence after resection
of hepatocellular carcinoma complicating cirrho-
sis.  Ann Surg 1991;214:114–117.
 4 Brandt B, Junker R, Griwatz C, Heidl S,
Brinkmann O, Semjonow A, et al.  Isolation of
prostate-derived single cells and cell clusters
from human peripheral blood.  Cancer Res 1996;
56:4556–4561.
 5 Chen P-J, Chen D-S, Lai M-Y, Chang M-H,
Huang G-T, Yang P-M, et al.  Clonal origin of
recurrent hepatocellular carcinomas.  Gastro-
enterology 1989;96:527–529.
 6 Gitlin D, Boesman M.  Serum α-fetoprotein,
albumin, and γG-Globulin in the human con-
ceptus.  J Clin Invest 1966;45:1826–1838.
 7 Heu H-C, Chiou T-J, Chen J-Y, Lee C-S, Lee P-
H, Peng S-Y.  Clonality and clonal evaluation of
hepatocellular carcinoma with multiple nodules.
Hepatology 1991;13:923–928.
 8 Inoue S, Nakao A, Harada A, Nonami T, Takagi
H.  Clinical significance of abnormal prothrom-
bin (DCP) in relation to postoperative survival
and prognosis in patients with hepatocellular
carcinoma.  Am J Gastroenterol 1994;89:2222–
2226.
 9 Ishikawa T, Kashiwagi H, Iwakami Y, Hirai M,
Kawamura T, Aiyoshi Y, et al.  Expression of α-
fetoprotein and prostate-specific antigen genes in
several tissues and detection of mRNA in normal
circulating blood by reverse transcriptase-poly-
merase chain reaction.  Jpn J Clin Oncol 1998;28:
723–728.
10 Jiang SY, Shyu R-Y, Huang M-F, Tang H-S, Young
H-S, Roffler SR, et al.  Detection of alphafeto-
protein-expressing cells in the blood of patients
with hepatoma and hepatitis.  Br J Cancer 1997;
75:928–933.
11 Komeda T, Fukuda Y, Sando T, Kita R, Furukawa
M, Nishida N, et al.  Sensitive detection of
circulating hepatocellular carcinoma cells in
peripheral venous blood.  Cancer 1995;75:2214–
2219.
12 Krüger W, Krzizanowski C, Holweg M,
Stockschläder M, Kröger N, Jung R, et al.  Reverse
transcriptase/polymerase chain reaction detection of
cytokeratin-19 mRNA in bone marrow and blood of
breast cancer patients.  J Cancer Res Clin Oncol
1996;122:679–686.
13 Kubo S, Nishiguchi S, Hirohashi K, Shuto T,
Kuroki T, Minamitani S, et al.  Clinicopatho-
logical criteria for multicentricity of hepato-
cellular carcinoma and risk factors for such
carcinogenesis.  Jpn J Cancer Res 1998;89:419–
426.
14 Kumada T, Nakano S, Takeda I, Sugiyama K,
Osada T, Kiriyama S, et al.  Pattens of recurrence
after initial treatment in patients with small
hepatocellular carcinoma.  Hepatology 1997;25:
87–92.
15 Lemoine A, Le Bricon T, Salvucci M, Azoulay
D, Pham P, Raccuia J, et al.  Prospective evalua-
tion of circulating hepatocytes buy alpha-fetopro-
tein mRNA in humans during liver surgery.  Ann
Surg 1997;226:43–50.
16 Louha M, Poussin K, Ganne N, Zylberberg H,
Nalpas B, Nicolet J, et al.  Spontaneous and iatro-
genic spreading of liver-derived cells into periph-
eral blood of patients with primary liver cancer.
Hepatology 1997;26:998–1005.
17 Luo W, Yatsuhashi H, Hamada R, Matsumoto T,
Inoue O, Koga M, et al.  Analysis of α-fetoprotein
mRNA in peripheral blood:  detection and semi-
quantitation by reverse transcription polymerase
chain reaction.  Hepatol Res 1999;14:1–12.
18 Matsumura M, Niwa Y, Hikida Y, Okano K,
Kato N, Shiina S, et al.  Sensitive assay for de-
tection of hepatocellular carcinoma associated
gene transcription (alpha-fetoprotein mRNA) in
blood.  Biochem Biophys Res Commun 1995;
207:813–818.
19 Matsumura M, Niwa Y, Kato N, Komatsu Y,
Shiina S, Kawabe T, et al.  Detection of α-
fetoprotein mRNA, an indicator of hematogenous
spreading hepatocellular carcinoma, in the
circulation:  a possible predictor of metastatic
hepatocellular carcinoma.  Hepatology 1994;20:
1418–1425.
20 Matsumura M, Shiratori Y, Niwa Y, Tanaka T,
Ogura K, Okudaira T, et al.  Presence of α-feto-
protein mRNA in blood correlates with outcome
in patients with hepatocellular carcinoma.  J
Hepatol 1999;31:332–339.
21 Mattano LA Jr, Moss TJ, Emerson SG.  Sensitive
detection of rare circulating neuroblastoma cells
by the transcriptase-polymerase chain reaction.
Cancer Res 1992;52:4701–4705.
22 Moreno JG, Croce CM, Fischer R, Monne M,
Vihko P, Mulholland SG, et al.  Detection of
hematogenous micrometastasis in patients with
prostate cancer.  Cancer Res 1992;52:6110–6112.
23 Nagasue N, Uchida M, Makino Y, Takemoto Y,
Yamanoi A, Hayashi T, et al.  Incidence and fac-
tors associated with intrahepatic recurrence fol-
lowing resection of hepatocellular carcinoma.
Gastroenterology 1993;105:488–494.
24 Nakagawa T, Seki T, Shiro T, Wakabayashi M,
AFP mRNA in blood of HCC patients
57
Imamura M, Itoh T, et al.  Clinicopathologic sig-
nificance of protein induced vitamin K absence or
antagonist II and a-fetoprotein in hepatocellular
carcinoma.  Intern J Oncol 1999;14:281–286.
25 Nakano S, Haratake J, Okamoto K, Takeda S.  In-
vestigation of resected  multinodular hepato-
cellular carcinoma:  assessment of unicentric or
multicentric genesis from histological and prog-
nostic viewpoint.  Am J Gastroenterol 1994;89:
189–193.
26 Nambu S, Nishimori H, Maekawa M, Higuchi K,
Watanabe A.  Plasma PIVKAII values as an
indicator of AFP mRNA in the circulation in pa-
tients with advanced hepatocellular carcinoma.
Hepatol Res 1997;8:28–36.
27 Nomoto S, Nakao A, Kasai Y, Harada A, Nonami
T, Takagi H.  Detection of ras gene mutations in
perioperative peripheral blood with pancreatic
adenocarcinoma.  Jpn J Cancer Res 1996;87:793–
799.
28 Nomura F, Ohnishi K, Tanabe Y.  Clinical fea-
tures and prognosis of hepatocellular carcinoma
with reference to serum alpha-fetoprotein levels.
Cancer 1989;64:1700–1707.
29 Okuda K.  Hepatocellular carcinoma:  recent
progress.  Hepatology 1992;15:948–963.
30 Okuda K, Kotoda K, Obata H, Hayashi N,
Hisamitsu T, Tamiya M, et al.  Clinical obser-
vations during a relatively early stage of hepato-
cellular carcinoma, with special reference to
serum α-fetoprotein levels.  Gastroenterology
1975;69:226–234.
31 Okuda N, Nakao A, Takeda S, Oshima K,
Kanazumi N, Nonami T, et al.  Clinical signifi-
cance of α-fetoprotein mRNA during periopera-
tive period in HCC.  Hepatogastroenterology
1999;46:381–386.
32 Omichi-Funaki N, Tanaka J, Imamura M.  Quan-
titative analysis of alpha fetoprotein mRNA in
circulating peripheral blood of patients with
hepatocellular carcinoma and alpha fetoprotein
producing gastric carcinoma.  Life Sci 1998;62:
1973–1984.
33 Omichi-Funaki N, Tanaka J, Seto S, Kasamatsu
T, Kaido T, Imamura M.  Hematogenous spread-
ing of hepatocellular carcinoma cells:  possible
participation in recurrence in the liver.  Hepatol-
ogy 1997;25:564–568.
34 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ,
Higuchi R, Horn GT, et al.  Primer-directed enzy-
matic amplification of DNA with a thermostable
DNA polymerase.  Science 1988;239:487–491.
35 Sheu J-C, Huang G-T, Chou H-C, Lee P-H,
Wang J-T, Lee H-S, et al.  Multiple hepatocellu-
lar carcinomas at the early stage have different
clonality.  Gastroenterology 1993;105:1471–
1476.
36 Smith B, Selby P, Southgate J, Pittman K,
Bradley C, Blair GE.  Detection of melanoma
cells in peripheral blood by means of reverse
transcriptase and polymerase chain reaction.
Lancet 1991;338:1227–1229.
37 Suehiro T, Sugimachi K, Matsumata T, Itasaka
H, Taketomi A, Maeda T.  Protein induced by
Vitamin K absence or antagonist II as prognostic
marker in hepatocellular carcinoma.  Cancer
1994;73:2464–2471.
38 Tada M, Omata M, Kawai S, Saisho H, Ohto M,
Saiki RK, et al.  Detection of ras gene mutation in
pancreatic juice and peripheral blood of patients
with pancreatic adenocarcinoma.  Cancer Res
1993;53:2572–2574.
39 Takenaka K, Adachi E, Nishizaki T, Hiroshige K,
Ikeda T, Tsuneyoshi M, et al.  Possible multi-
centric occurrence of hepatocellular carcinoma:
a clinicopathological study.  Hepatology 1994;
19:889–894.
40 Tarao K, Hoshino H, Shimizu A, Ohkawa S,
Nakamura Y, Harada M, et al.  Role of increased
DNA synthesis activity of hepatocytes in multi-
centric hepatocarcinogenesis in residual liver of
hepatectomized cirrhotic patients with hepato-
cellular carcinoma.  Jpn J Cancer Res 1994;85:
1040–1044.
41 Toyosaka A, Okamoto E, Mitsunobu M, Oriyama
T, Nakao N, Miura K.  Intrahepatic metastasis in
hepatocellular carcinoma:  evidence for spread
via the portal vein as an efferent vessel.  Am J
Gastroenterol 1996;91:1610–1615.
42 Wong IH-N, Leung T, Ho S, Law WY, Chan M,
Johnson PJ.  Semiquantification of circulating
hepatocellular carcinoma cells by reverse tran-
scriptase polymerase chain reaction.  Br J Cancer
1997;76:628–633.
43 Yokoyama I, Todo S, Iwatsuki S, Starzl TE.
Liver transplantation in the treatment of primary
liver cancer.  Hepatogastroenterology 1990;37:
188–193.
44 Zhou X-D, Tang Z-Y, Yang B-H, Yu Y-Q, Lin Z-
Y, Lu J-Z, et al.  Long-term results of surgery for
small primary liver cancer in 514 adults.  J Cancer
Res Clin Oncol 1996;122:59–62.
(Received December 16, 1999, Accepted January 5, 2000)
